In 233 evaluable patients, median overall survival was 22.8 months with SurVaxM and 20.3 months with placebo (HR, 0.75; P = .076).
2
Among patients aged 65 years and younger, median overall survival was 24.2 months with SurVaxM and 20.2 months with placebo (HR, 0.64; P = .019).
3
In patients aged 65 years and younger, SurVaxM improved progression-free survival (HR, 0.64; P = .018), and 12-month progression-free survival was 44% vs 24% with placebo.
4
Among SurVaxM-treated patients aged 65 years and younger, 42% were alive at 30 months or longer, compared with 18% of placebo recipients.
5
Grade 3 or higher adverse event rates were 48% with SurVaxM and 46% with placebo; no treatment-related deaths occurred in either group.
